On the evening of November 26, Cansino announced that the company's ACYW135 meningococcal polysaccharide conjugate vaccine drug supplement application recently obtained a “Notice of Acceptance” issued by the State Drug Administration. This supplementary application expands the age range of people applicable to MCV4 from “children aged 3 months to 3 years” to “children aged 3 months to 6 years.” MCV4 Manhisin® is China's first meningococcal quadrivalent conjugate vaccine product. Its launch has narrowed the gap between China and developed countries in this field, filled the gap between China's lack of high-end vaccines in this field, and provided a better solution for preventing encephalitis in infants and young children in China.

Zhitongcaijing · 11/26 09:25
On the evening of November 26, Cansino announced that the company's ACYW135 meningococcal polysaccharide conjugate vaccine drug supplement application recently obtained a “Notice of Acceptance” issued by the State Drug Administration. This supplementary application expands the age range of people applicable to MCV4 from “children aged 3 months to 3 years” to “children aged 3 months to 6 years.” MCV4 Manhisin® is China's first meningococcal quadrivalent conjugate vaccine product. Its launch has narrowed the gap between China and developed countries in this field, filled the gap between China's lack of high-end vaccines in this field, and provided a better solution for preventing encephalitis in infants and young children in China.